Atomoxetine for attention deficit/hyperactivity disorder.
Seven randomized, double-blinded, controlled trials in children, adolescents and adults have shown that atomoxetine improves attention deficit/hyperactivity disorder (ADHD) symptoms compared to placebo. There is no evidence that atomoxetine has greater efficacy or a better safety profile than currently used therapy. Atomoxetine has been submitted for regulatory approval in Canada and is currently approved in the US. The price of atomoxetine in Canada has not been established.
Kirsten
K
Garces
D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D002170:Canada; D002648:Child; D003365:Costs and Cost Analysis; D017277:Drug Approval; D006801:Humans; D015990:Placebo Effect; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000928:Antidepressive Agents; D011437:Propylamines